Cargando…
A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital
Background: Bamlanivimab and casirivimab/imdevimab are recombinant neutralizing monoclonal antibodies that decrease viral load in patients with coronavirus disease 2019 (COVID-19) and can decrease hospitalizations. Few data exist comparing these two therapies. Objective: Our aim was to compare the e...
Autores principales: | Farcy, David A., Dalley, Michael T., Miro, Grethel, Swalley, Paige, Sherman, Dana, Nash, Joel, Jodoin, Kathleen, Cubeddu, Luigi X., Zitek, Tony, Goldszer, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279938/ https://www.ncbi.nlm.nih.gov/pubmed/34489146 http://dx.doi.org/10.1016/j.jemermed.2021.07.025 |
Ejemplares similares
-
Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19
por: Zitek, Tony, et al.
Publicado: (2022) -
Does a Standardized Discharge Communication Tool Improve Resident Performance and Overall Patient Satisfaction?
por: Dalley, Michael T., et al.
Publicado: (2021) -
Is Serum Lactate Necessary in Patients with Normal Anion Gap and Serum Bicarbonate?
por: Aronovich, Daniel, et al.
Publicado: (2015) -
Pediatric Ingestion of Multiple Button Batteries
por: Fong, Johnny, et al.
Publicado: (2019) -
A man with an ocular mass
por: Zitek, Tony, et al.
Publicado: (2022)